GHRP-2 Mechanism of Action — Research Reference

GHRP-2 (Pralmorelin; D-Ala-D-2-Nal-Ala-Trp-D-Phe-Lys-NH2) is a hexapeptide growth hormone secretagogue and one of the most pharmacologically active members of the GHRP class.

Receptor Target

GHRP-2 is a potent agonist of the growth hormone secretagogue receptor type 1a (GHS-R1a) — the ghrelin receptor. Compared to ipamorelin, its binding is less restricted: at GH-effective doses it produces measurable secondary effects on the hypothalamic-pituitary-adrenal axis.

Signal Transduction

Like other GHRPs, GHRP-2 signalling proceeds through:

1. Gαq/11 → PLC-β → IP3/DAG → intracellular Ca²⁺ release.
2. Gαs → cAMP → PKA — secondary contribution potentiating GHRH signalling.
3. Inhibition of somatostatinergic tone at the hypothalamus.

Why Cortisol and Prolactin Rise

GHRP-2 binding extends to corticotrope and lactotrope populations expressing GHS-R1a (or homologous receptors). Published dose-response work consistently shows acute ACTH and prolactin elevation 30–60 minutes after dosing — typically modest at research doses but clearly distinguishable from ipamorelin's clean profile.

Pharmacokinetics

Subcutaneous GHRP-2 produces a rapid GH pulse peaking near 15–30 minutes. Half-life is approximately 15–25 minutes. The D-amino acid scaffold provides resistance to peptidase cleavage.

Synergy with GHRH Analogues

GHRP-2 + a GHRH analogue (CJC-1295, sermorelin) produces the same synergistic GH release described for the ipamorelin/GHRH combination. Researchers favouring GHRP-2 over ipamorelin typically prioritize the larger acute GH-pulse amplitude.

Research Use Only. All content is for laboratory research and educational reference. Compounds discussed are not intended for human or veterinary consumption.

References

1. Bowers CY. GH releasing peptides — structure and kinetics. J Pediatr Endocrinol. 1993;6(1):21–31.
2. Bowers CY. Editorial: a new dimension on the induced release of growth hormone in obese subjects. J Clin Endocrinol Metab. 1993;76(3):817–818.
3. Sigalos JT, Pastuszak AW. The Safety and Efficacy of Growth Hormone Secretagogues. Sex Med Rev. 2018;6(1):45–53.